The OncoAlert Network🚨 is pleased to present its collective expert view on the PROSPECT clinical trial for rectal cancer presented at #ASCO23 As a leading source of timely and reliable information in oncology, we are honored to contribute our consensus opinion on this study. In line with our commitment, and in agreement with the statements from our Partners at @astro and our colleagues at @ESTRO_RT Here is our official stance on the PROSPECT trial as drafted by our @OncoAlert RadiationTherapy☢️& GI Oncology faculty, inclusive of Patient Advocates. The OncoAlert Network🌐 acknowledges the influence of the PROSPECT trial on the management of #RectalCancer. Given the intricate nature of this disease, our esteemed panel of experts has diligently examined the existing data and is eager to present the following discerning observations:

Here’s the dirty secret of emergency medicine: We don’t have to do prior auth. Like ever. We just order what the patient needs, and the patient gets it done in the ED. But here’s why we care about prior auth anyways: B/c not a shift goes by where a patient doesn’t land in the ER as a last resort when #priorauth denied or delayed them the outpatient care they needed.

This is very real and we are running short of the most common chemo (carbo/cisplatin) used in almost every patient with lung cancer, hundreds of thousands of people in the US. If the govt can step in same day to save a bank why not to ensure needed drugs for cancer pts? @ASCO

“Ra­di­a­tion is less tax­ing and more tar­geted than it used to be, and some pa­tients can get the same ben­e­fits in fewer ses­sions” “I had heard so many war sto­ries about can­cer, but it’s changed so much,” she said.” wsj.com/articles/cancer-pati…

Doctors at a major US insurance company deny tens of thousands of claims a month without even looking at patients’ files. “We literally click & submit,” a former Cigna doctor told @ProPublica & @Capitol_Forum. “It takes all of 10 seconds to do 50 at a time.” The inside story 🧵

Nindantenib v pbo for radiation pneumonitis: - Randomized ph II trial, 1:1 with 8 wk pred taper in both arms - 30 evaluable pts - 72% v 40% free from pulm exacerbations (primary endpt) in favor of nindantenib (p=0.037) @OncoAlert @MSKCancerCenter #LCSM redjournal.org/article/S0360…

Honored to be featured on @QuadShotNews today! Thank you for sharing our work 😊 @TheFeldmanMD @HenryFordHealth